罗伟生治疗乙肝肝硬化的经验
|
摘要
罗伟生教授经过多年的临床经验,在治疗乙肝肝硬化方面积累了独特的经验和心得,其认为正气不足是乙肝肝硬化发病的基础,而瘀血阻络为该病关键病机所在,在治疗上注重驱邪与扶正并进,疏肝柔肝并举,并常在辨证论治的基础上搭配单味有效中药的使用,获得良好疗效,为乙肝肝硬化治疗提供了有效的方法和治疗思路。
Professor Luo Wei-sheng has accumulated unique experience in the treatment of hepatitis B cirrhosis after many years of clinical experience. He believes that insufficient vital energy is the basis of the pathogenesis of hepatitis B cirrhosis. Blood stasis and collateral obstruction are the key pathogenesis of the disease. He pays attention to both exorcising pathogens and strengthening the integrity, soothing the liver and softening the liver, and often combines the use of single effective traditional Chinese medicine on the basis of syndrome differentiation and treatment. It has good curative effect and provides effective methods and treatment ideas for the treatment of hepatitis B cirrhosis.
Professor Luo Wei-sheng has accumulated unique experience in the treatment of hepatitis B cirrhosis after many years of clinical experience. He believes that insufficient vital energy is the basis of the pathogenesis of hepatitis B cirrhosis. Blood stasis and collateral obstruction are the key pathogenesis of the disease. He pays attention to both exorcising pathogens and strengthening the integrity, soothing the liver and softening the liver, and often combines the use of single effective traditional Chinese medicine on the basis of syndrome differentiation and treatment. It has good curative effect and provides effective methods and treatment ideas for the treatment of hepatitis B cirrhosis.
引文
[1]葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013.
[2]李梦培,李静.乙肝肝硬化的治疗进展[J].辽宁医学院学报,2016,37(3):100-102.
[3]张连俊,左亚东.中医药治疗慢性乙型肝炎肝纤维化的研究进展[J].中医临床研究,2015,7(2):145-147.
[4]庄灿皇.基于近二十年文献中医药治疗肝纤维化的方药规律研究[D].广州:广州中医药大学,2016.
[5]张介宾(明).景岳全书[M].北京:人民卫生出版社,2014.
[6]太平惠民合剂局.《太平惠民合剂局方》[M].北京:人民卫生出版社,2007.
[7]范婷婷,谢渭芬.肝纤维化和肝硬化治疗进展[J].国际消化病杂志,2010,30(6):349-351.
[8]张菊艳,张萃.荔枝核化学成分及其药理作用的研究进展[J].广东药学院学报,2014,6:792-797.
[9]肖柳英,曾文铤,马佩球,等.荔枝核颗粒剂治疗慢性乙型肝炎临床疗效研究[J].中华中医药杂志,2005,20(7):444-445.
[10]汤建萍,丁立稳,周春山.紫外分光光度法测定荔枝核抗乙肝成分的含量[J].时珍国医国药,2006,17(11):2218-2219.
[11]陈华妮,潘洁萍,黄小丹,等.响应曲面法优化野生酸荔枝核中抗乙肝成分的提取工艺[J].中国实验方剂学杂志,2014,20(18):41-44.
[12]徐庆,宋芸娟,李丽亚.荔枝核总黄酮的抗鸭乙型肝炎病毒作用[J].世界华人消化杂志,2005,13(17):2082-2085.
[13]肖柳英,潘竞锵,饶卫农.荔枝核对小鼠肝炎动物模型的实验研究[J].中国实用医药,2006,1(1):11-13.
[14]Duval F,Morenocuevas J E,Rodríguezmontalvo C,et al.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis[J].Chinese Medicine,2014,9(1):27.
[15]陈岳祥,李石,范列英,等.丹参单体IH764-3抗肝纤维化作用的实验研究[J].中华医学杂志,1998,78(8):76-77.
[16]董颖,张翼宙.丹参有效成分抗肝纤维化分子机制研究进展[J].山西中医学院学报,2014,15(2):63-66.
[2]李梦培,李静.乙肝肝硬化的治疗进展[J].辽宁医学院学报,2016,37(3):100-102.
[3]张连俊,左亚东.中医药治疗慢性乙型肝炎肝纤维化的研究进展[J].中医临床研究,2015,7(2):145-147.
[4]庄灿皇.基于近二十年文献中医药治疗肝纤维化的方药规律研究[D].广州:广州中医药大学,2016.
[5]张介宾(明).景岳全书[M].北京:人民卫生出版社,2014.
[6]太平惠民合剂局.《太平惠民合剂局方》[M].北京:人民卫生出版社,2007.
[7]范婷婷,谢渭芬.肝纤维化和肝硬化治疗进展[J].国际消化病杂志,2010,30(6):349-351.
[8]张菊艳,张萃.荔枝核化学成分及其药理作用的研究进展[J].广东药学院学报,2014,6:792-797.
[9]肖柳英,曾文铤,马佩球,等.荔枝核颗粒剂治疗慢性乙型肝炎临床疗效研究[J].中华中医药杂志,2005,20(7):444-445.
[10]汤建萍,丁立稳,周春山.紫外分光光度法测定荔枝核抗乙肝成分的含量[J].时珍国医国药,2006,17(11):2218-2219.
[11]陈华妮,潘洁萍,黄小丹,等.响应曲面法优化野生酸荔枝核中抗乙肝成分的提取工艺[J].中国实验方剂学杂志,2014,20(18):41-44.
[12]徐庆,宋芸娟,李丽亚.荔枝核总黄酮的抗鸭乙型肝炎病毒作用[J].世界华人消化杂志,2005,13(17):2082-2085.
[13]肖柳英,潘竞锵,饶卫农.荔枝核对小鼠肝炎动物模型的实验研究[J].中国实用医药,2006,1(1):11-13.
[14]Duval F,Morenocuevas J E,Rodríguezmontalvo C,et al.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis[J].Chinese Medicine,2014,9(1):27.
[15]陈岳祥,李石,范列英,等.丹参单体IH764-3抗肝纤维化作用的实验研究[J].中华医学杂志,1998,78(8):76-77.
[16]董颖,张翼宙.丹参有效成分抗肝纤维化分子机制研究进展[J].山西中医学院学报,2014,15(2):63-66.